Stadtmauer, E., Karlin, L., Weisel, K., Gatt, M. E., Kansagra, A., Monohan, G., … Gasparetto, C. (2021). 448 Lemzoparlimab (TJ011133), an anti-CD47 antibody, with/without dexamethasone plus anti-myeloma regimens for relapsed/refractory multiple myeloma: a phase 1b dose escalation and expansion study. In Regular and Young Investigator Award Abstracts (pp. A476–A476). BMJ Publishing Group Ltd. https://doi.org/10.1136/jitc-2021-sitc2021.448

Stadtmauer, Edward, Lionel Karlin, Katja Weisel, Moshe Etzion Gatt, Ankit Kansagra, Gregory Monohan, Andrew Yee, et al. “448 Lemzoparlimab (TJ011133), an anti-CD47 antibody, with/without dexamethasone plus anti-myeloma regimens for relapsed/refractory multiple myeloma: a phase 1b dose escalation and expansion study.” In Regular and Young Investigator Award Abstracts, A476–A476. BMJ Publishing Group Ltd, 2021. https://doi.org/10.1136/jitc-2021-sitc2021.448.

Stadtmauer E, Karlin L, Weisel K, Gatt ME, Kansagra A, Monohan G, et al. 448 Lemzoparlimab (TJ011133), an anti-CD47 antibody, with/without dexamethasone plus anti-myeloma regimens for relapsed/refractory multiple myeloma: a phase 1b dose escalation and expansion study. In: Regular and Young Investigator Award Abstracts. BMJ Publishing Group Ltd; 2021. p. A476–A476.

Stadtmauer, Edward, et al. “448 Lemzoparlimab (TJ011133), an anti-CD47 antibody, with/without dexamethasone plus anti-myeloma regimens for relapsed/refractory multiple myeloma: a phase 1b dose escalation and expansion study.” Regular and Young Investigator Award Abstracts, BMJ Publishing Group Ltd, 2021, pp. A476–A476. Crossref, doi:10.1136/jitc-2021-sitc2021.448.

Stadtmauer E, Karlin L, Weisel K, Gatt ME, Kansagra A, Monohan G, Yee A, Rockow-Magnone S, Cordero J, Hoffman D, Bueno O, Wu K, Gasparetto C. 448 Lemzoparlimab (TJ011133), an anti-CD47 antibody, with/without dexamethasone plus anti-myeloma regimens for relapsed/refractory multiple myeloma: a phase 1b dose escalation and expansion study. Regular and Young Investigator Award Abstracts. BMJ Publishing Group Ltd; 2021. p. A476–A476.